STOCK TITAN

Verve Therapeutics Inc - VERV STOCK NEWS

Welcome to our dedicated news page for Verve Therapeutics (Ticker: VERV), a resource for investors and traders seeking the latest updates and insights on Verve Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Verve Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Verve Therapeutics's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.74%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.5%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.73%
Tags
conferences
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.83%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.93%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.2%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.48%
Tags
conferences
Verve Therapeutics Inc

Nasdaq:VERV

VERV Rankings

VERV Stock Data

635.51M
66.88M
7.65%
88.06%
18.37%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Cambridge

About VERV

verve therapeutics is a biotechnology company created with a singular focus: to protect the world from heart disease. the company brings together human genetics analysis and gene editing – two of the biggest breakthroughs in 21st century biomedicine – to develop transformative therapies for coronary heart disease. verve is developing medicines, administered once in life, to safely edit the genome of adults to permanently lower ldl cholesterol and triglyceride levels and thereby treat coronary heart disease. founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, verve is backed by a top-tier syndicate of investors, including gv (formerly google ventures), arch venture partners, f-prime capital, biomatics capital, wellington management, casdin capital, and partners innovation fund. the company was recognized as a "2020 best places to work" by the boston business journal. verve is headquartered in cambridge, massachusetts.